JP2013501816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501816A5 JP2013501816A5 JP2012524910A JP2012524910A JP2013501816A5 JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5 JP 2012524910 A JP2012524910 A JP 2012524910A JP 2012524910 A JP2012524910 A JP 2012524910A JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- combination
- erythropoietin receptor
- medicament according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 20
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 20
- 239000012190 activator Substances 0.000 claims description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 11
- 102000003951 Erythropoietin Human genes 0.000 claims description 10
- 108090000394 Erythropoietin Proteins 0.000 claims description 10
- 229940105423 erythropoietin Drugs 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 5
- 108010019673 Darbepoetin alfa Proteins 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000010437 erythropoiesis Effects 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 108700022380 synthetic erythropoiesis Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims description 2
- 102100031939 Erythropoietin Human genes 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000003173 antianemic agent Substances 0.000 claims description 2
- 229940115115 aranesp Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 2
- 229960005029 darbepoetin alfa Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960003388 epoetin alfa Drugs 0.000 claims description 2
- 108010002601 epoetin beta Proteins 0.000 claims description 2
- 229960004579 epoetin beta Drugs 0.000 claims description 2
- 108010067416 epoetin delta Proteins 0.000 claims description 2
- 229950002109 epoetin delta Drugs 0.000 claims description 2
- 108010090921 epoetin omega Proteins 0.000 claims description 2
- 229950008767 epoetin omega Drugs 0.000 claims description 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 208000037806 kidney injury Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 238000011284 combination treatment Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/583,177 | 2009-08-13 | ||
| US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
| USPCT/US2009/004659 | 2009-08-13 | ||
| PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
| US30590110P | 2010-02-18 | 2010-02-18 | |
| US61/305,901 | 2010-02-18 | ||
| PCT/US2010/045509 WO2011020045A1 (en) | 2009-08-13 | 2010-08-13 | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Division JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501816A JP2013501816A (ja) | 2013-01-17 |
| JP2013501816A5 true JP2013501816A5 (cg-RX-API-DMAC7.html) | 2013-09-19 |
| JP5909446B2 JP5909446B2 (ja) | 2016-04-26 |
Family
ID=43586530
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Active JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP3838919A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP5909446B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR101882521B1 (cg-RX-API-DMAC7.html) |
| CN (7) | CN105535938B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010282361B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112012003232B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2770822C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2796121T3 (cg-RX-API-DMAC7.html) |
| IL (6) | IL287990B (cg-RX-API-DMAC7.html) |
| MX (2) | MX2012001916A (cg-RX-API-DMAC7.html) |
| NZ (3) | NZ598348A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2592670C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011020045A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| JP5574711B2 (ja) | 2007-02-09 | 2014-08-20 | アクセルロン ファーマ， インコーポレイテッド | 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用 |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| CN107837390A (zh) * | 2011-10-17 | 2018-03-27 | 阿塞勒隆制药公司 | 用于治疗无效性红细胞生成的方法和组合物 |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CN112933223A (zh) * | 2012-10-24 | 2021-06-11 | 细胞基因公司 | 用于治疗贫血的方法 |
| CN113604550A (zh) * | 2012-10-24 | 2021-11-05 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| JP2017509647A (ja) * | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| AP2017009674A0 (en) * | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3922259A1 (en) * | 2014-10-30 | 2021-12-15 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3256148A1 (en) * | 2015-02-12 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| JP6959487B2 (ja) | 2015-04-22 | 2021-11-02 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
| WO2016187378A1 (en) * | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| WO2017091706A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CA3014197A1 (en) * | 2016-02-22 | 2017-08-31 | Ravindra Kumar | Actrii antagonists for use in increasing immune activity |
| RS62011B1 (sr) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
| RS65735B1 (sr) | 2016-07-27 | 2024-08-30 | Acceleron Pharma Inc | Kompozicije za upotrebu u lečenju mijelofibroze |
| CN110036025B (zh) * | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| AU2017340504A1 (en) | 2016-10-05 | 2019-04-11 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7496686B2 (ja) | 2017-06-14 | 2024-06-07 | セルジーン コーポレイション | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| CA3098679A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| US12310982B2 (en) | 2018-12-10 | 2025-05-27 | Elena Valentinovna ARSHINTSEVA | Use of the poloxamer as a pharmacologically active substance |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN115317589B (zh) * | 2022-09-05 | 2024-12-13 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
| CN119198238A (zh) * | 2024-09-18 | 2024-12-27 | 广东省安家医健健康管理有限公司 | 一种地中海贫血检测系统及试剂盒 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| WO1996032503A1 (en) | 1995-04-11 | 1996-10-17 | The General Hospital Corporation | Reverse two-hybrid systems |
| WO2000043781A2 (en) | 1999-01-21 | 2000-07-27 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| ATE291436T2 (de) * | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20030176317A1 (en) * | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE602004018902D1 (de) * | 2003-02-07 | 2009-02-26 | Prometic Biosciences Inc | Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese |
| GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| JP2008522621A (ja) * | 2004-12-09 | 2008-07-03 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン |
| KR20080003929A (ko) * | 2005-04-26 | 2008-01-08 | 아지노모토 가부시키가이샤 | 골수 적혈구 전구 세포 분화 촉진제 |
| ATE521629T1 (de) * | 2005-10-07 | 2011-09-15 | Angeletti P Ist Richerche Bio | Matrixmetalloproteinase-11-impfstoff |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008073292A2 (en) * | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| AU2007334333B2 (en) * | 2006-12-18 | 2013-05-30 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| TW201940502A (zh) * | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| WO2009158015A2 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| WO2010019261A1 (en) * | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
-
2010
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active Active
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en not_active Ceased
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 CN CN202110421547.9A patent/CN113171442B/zh active Active
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Ceased
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
- 2010-08-13 CN CN202110417494.3A patent/CN113082194B/zh active Active
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active Active
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active Active
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko not_active Ceased
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2017
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501816A5 (cg-RX-API-DMAC7.html) | ||
| Parvez et al. | PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment | |
| Hamid et al. | Intratumoral immunotherapy—update 2019 | |
| RU2012109393A (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| Arnold et al. | The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules | |
| Adamali et al. | Current and novel drug therapies for idiopathic pulmonary fibrosis | |
| Chuntova et al. | Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy | |
| Koh et al. | Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage | |
| US10525106B2 (en) | Angiopoietin-based interventions for treating cerebral malaria | |
| JP2017533910A5 (cg-RX-API-DMAC7.html) | ||
| Gholami et al. | A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer | |
| Brunckhorst et al. | Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2017501381A5 (cg-RX-API-DMAC7.html) | ||
| Sharma | Interleukin-6 trans-signaling: a pathway with therapeutic potential for diabetic retinopathy | |
| Greene et al. | Targeting transcription factors ATF5, CEBPB and CEBPD with cell-penetrating peptides to treat brain and other cancers | |
| JP2017530130A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517658A5 (cg-RX-API-DMAC7.html) | ||
| Nowacka et al. | Angiogenesis in glioblastoma—treatment approaches | |
| JP2015514115A5 (cg-RX-API-DMAC7.html) | ||
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma | |
| Lu et al. | Vascular endothelial growth factor B promotes transendothelial fatty acid transport into skeletal muscle via histone modifications during catch-up growth | |
| Arkless et al. | CGRP discovery and timeline | |
| Oglesby et al. | Intratumoral and combination therapy in melanoma and other skin cancers |